Drug Profile
Iltamiocel - Cook MyoSite
Alternative Names: AMDC - Cook MyoSite; AMDC-USR; Autologous muscle derived cells - Cook MyoSite; Autologous muscle derived stem cell therapy - Cook MyoSite; Autologous muscle derived stem cells - Cook MyoSite; CMI-AMDCLatest Information Update: 11 Dec 2023
Price :
$50
*
At a glance
- Originator Cook MyoSite
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Faecal incontinence; Stress incontinence
- Phase II Bladder dysfunction
- Discontinued Ischaemic heart disorders
Most Recent Events
- 01 Dec 2023 Phase-III clinical trials in Faecal Incontinence (Treatment-experienced) in USA (Parenteral) (NCT05776277)
- 20 Mar 2023 Cook MyoSite plans a phase III DigniFI trial for Faecal Incontinence (Treatment-experienced) (Parenteral, Injection) (NCT05776277)
- 27 Oct 2021 Cook MyoSite completes a phase I/II trial in Fecal incontinence in the UK and Canada (NCT01600755) (EudraCT2013-004672-35)